Lv31
280 积分 2022-09-26 加入
The DEBBRAH trial: Trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer patients with leptomeningeal carcinomatosis
9天前
已完结
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
11天前
已完结
Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial
12天前
已完结
Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial
12天前
已完结
The Role of Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer
13天前
已完结
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
14天前
已完结
Trastuzumab rezetecan, a HER2-directed antibody–drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study
26天前
已完结
Prevalence of depressive disorders and treatment in China: a cross-sectional epidemiological study
6个月前
已完结
The landscape of reported VUS in multi-gene panel and genomic testing: Time for a change
7个月前
已完结
Transcription-targeted DNA deamination by the AID antibody diversification enzyme
7个月前
已完结
皖公网安备34019202002308
